Astrazeneca Gilead

Astrazeneca

Astrazeneca, Gilead Could Be In Merger Talks Amid Race to Find Covid19 Vaccine

A hypothetical merger would result in the world’s largest Health-Care group. In dollar terms, AstraZeneca’s capitalisation is 141 bn$, with the stock price appreciating 41% in the last twelve months. Meanwhile, Gilead’s capitalisation stands at 96 bn$ and its share price has gained 19% in the same period. Everything points to Gilead preferring to develop very promising drugs on its own, in fields such as HIV or COVID-19.